Clinical and Histopathological Outcomes of High-Purity Type I Collagen in Chronic Wounds: A Systematic Review of Four Randomized Controlled Trials

Chronic wounds such as venous leg ulcers (VLUs), pressure ulcers (PUs), diabetic foot ulcers (DFUs), and full-thickness wounds (FTWs) are characterized by impaired angiogenesis, persistent inflammation, and extracellular matrix (ECM) degradation. High-purity type I collagen (HPTC) is a biomimetic scaffold designed to restore physiological wound healing by enhancing vascularization, fibroblast activation, and collagen deposition. A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020-guided systematic search of PubMed, ClinicalTrials.gov, and Google Scholar was conducted. Inclusion criteria were randomized controlled trials (RCTs) comparing HPTC with dHACM or NPWT. Cochrane RoB-2 was applied for risk-of-bias assessment. A total of four RCTs evaluating VLUs (n=60), PUs (n=80), DFUs (n=120), and FTWs (n=104) were included in this review and analysed. All four RCTs (n=364 patients) had HPTC consistently outperforming comparators in closure rates (70-87% vs. 42-62%), wound-area reduction (78-89% vs. 58-65%), and healing time. Histopathological evaluation demonstrated significantly better vascular infiltration (+0.78 on a 0-3 scale), increased capillary density (+16.5 vessels/mm²), higher fibroblast activity (+0.88), improved collagen deposition (+0.96), reduced inflammatory infiltrate (-0.86), and enhanced neo-epithelialization (+0.94). Adverse events were fewer with HPTC (11.5% vs. 34.6%). Across all four RCTs, HPTC consistently outperformed dHACM and NPWT alone in both clinical and histopathological outcomes, demonstrating faster healing, improved microvascularization, enhanced fibroblast activity, better collagen organization, and reduced inflammation. The strong concordance between early tissue-level regeneration and long-term closure outcomes positions HPTC as a superior biological scaffold for chronic and full-thickness wound management. Its versatility, safety, and synergy with NPWT support its use as a frontline advanced wound therapy.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2026-01-03
DOI
https://doi.org/10.7759/cureus.100717
Citations
1
Primary Topic
Wound Healing and Treatments
Type
article
Field-Weighted Citation Impact
28.11
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical and Histopathological Outcomes of High-Purity Type I Collagen in Chronic Wounds: A Systematic Review of Four Randomized Controlled Trials

Kamal Kumar M, Naveen Narayan, Rajesh K Nanjundaiah, Usha Nareddula
1 citations
Cureus
Wound Healing and Treatments
28.11
article

Clinical and Histopathological Outcomes of High-Purity Type I Collagen in Chronic Wounds: A Systematic Review of Four Randomized Controlled Trials

Kamal Kumar M, Naveen Narayan, Rajesh K Nanjundaiah, Usha Nareddula
article en
1 citations

Abstract

Chronic wounds such as venous leg ulcers (VLUs), pressure ulcers (PUs), diabetic foot ulcers (DFUs), and full-thickness wounds (FTWs) are characterized by impaired angiogenesis, persistent inflammation, and extracellular matrix (ECM) degradation. High-purity type I collagen (HPTC) is a biomimetic scaffold designed to restore physiological wound healing by enhancing vascularization, fibroblast activation, and collagen deposition. A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020-guided systematic search of PubMed, ClinicalTrials.gov, and Google Scholar was conducted. Inclusion criteria were randomized controlled trials (RCTs) comparing HPTC with dHACM or NPWT. Cochrane RoB-2 was applied for risk-of-bias assessment. A total of four RCTs evaluating VLUs (n=60), PUs (n=80), DFUs (n=120), and FTWs (n=104) were included in this review and analysed. All four RCTs (n=364 patients) had HPTC consistently outperforming comparators in closure rates (70-87% vs. 42-62%), wound-area reduction (78-89% vs. 58-65%), and healing time. Histopathological evaluation demonstrated significantly better vascular infiltration (+0.78 on a 0-3 scale), increased capillary density (+16.5 vessels/mm²), higher fibroblast activity (+0.88), improved collagen deposition (+0.96), reduced inflammatory infiltrate (-0.86), and enhanced neo-epithelialization (+0.94). Adverse events were fewer with HPTC (11.5% vs. 34.6%). Across all four RCTs, HPTC consistently outperformed dHACM and NPWT alone in both clinical and histopathological outcomes, demonstrating faster healing, improved microvascularization, enhanced fibroblast activity, better collagen organization, and reduced inflammation. The strong concordance between early tissue-level regeneration and long-term closure outcomes positions HPTC as a superior biological scaffold for chronic and full-thickness wound management. Its versatility, safety, and synergy with NPWT support its use as a frontline advanced wound therapy.

CureusVol. 18(1)
JSS Academy of Higher Education and Research (IN), Rajarajeswari Medical College and Hospital (IN), Institute of Medical Sciences (IN)
Good health and well-being
Openalex Percentile: Top 3%
Wound Healing and Treatments
28.11
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.